Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/627,591 TRANSMITTAL Filing Date July 25, 2003 First Named Inventor **FORM** Andrew Clark et al. Art Unit 1614 **Examiner Name** Unassigned (to be used for all correspondence after initial filing) Attorney Docket Number 0029.10 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): 2 Cited References Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name NEKTIAR THERAPEUTICS Signature Printed name Guy V. Tucker Date Reg. No. VL 2000 45,302

# CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Typed or printed name Minna Cotter Date 19 JULOS

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**PATENT** 

OIF	E
JUL 2	1 2005 &
THE THA	DEMANDE the

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the application of: Andrew Clark et al.	)	Atty. Docket No.: 0029.10
	)	Examiner: Unassigned
Application No.: 10/627,591	)	Group Art Unit: 1614
Filed: July 25, 2003	)	
Title: AEROSOLIZED ACTIVE AGENT DELIVERY	)	•

### **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on 19 Julio 5

Signed: Munio Cotta

# 2<sup>nd</sup> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08A and B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

Copies of the references are enclosed, as required under 37 CFR §§1.98.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

	$\boxtimes$	within three months	of the fil	ling date of a national application or an RCE; within three
		months of the date of	f entry o	f the national stage as set forth in section 1.491 in an
		international applicate merits (whichever ev		pefore the mailing date of a first Office action on the ars last);
	Please	charge the amount of	<u>\$</u> to	Deposit Account 500348
$\boxtimes$		determined that any ac such fees to Deposit A		fees are due, the Commissioner is hereby authorized to 500348.
				Respectfully submitted,
				NEKTAR THERAPEUTICS
Dated:	191	VL WUS	Ву:	Guy V. Tucker Reg. No. 45, 302

San Carlos, CA 94070 (650) 631-3100

OIPE	CA.		
JUL 2 1 2003	Form PTO/SB/08A (Modified)	Atty Docket No.:	Application No.:
PE.	<b>&amp;/</b>	0029.10	10/627,591
PETTE TRADENT	Information Disclosure	Applicant:	
)	Statement By Applicant	Andrew	Clark et al.
		Filing Date:	Group:
	(Use Several Sheets if Necessary)	07/25/2003	1614

# **Other Documents**

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication						
	*	91/14468	10/03/1991	wo	T		<u> </u>	<u> </u>
	*	92/20391	11/26/1992	WO	<del> </del>			
					<u> </u>			
			<u> </u>		ļ			L
					ļ			
					ļ			ļ
					ļ			ļ
	-	<del></del>					_	ļ
	-							
					ļ			ļ
	<del>                                     </del>							
	-				-			_
					<del>                                     </del>			
					<del>                                     </del>			
				•				
	<u> </u>							

Examiner:	Date Considered:	

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.